title: Methotrexate for Inflammatory Bowel Diseases - New Developments.
abstract: Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, N.C., USA.
authors.forename: Hans H
authors.initials: HH
authors.lastname: Herfarth
mesh_terms: D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate